Impact of renal-adjusted ceftazidime/avibactam in patients with KPC-producing <i>Klebsiella pneumoniae</i> bloodstream infection: a retrospective cohort study.

ABSTRACT:

Background

Bloodstream infections (BSIs) caused by KPC-producing Klebsiella pneumoniae (KPC-Kp) are still associated with high mortality, and the game-changing drug ceftazidime/avibactam has shown suboptimal pharmacokinetics in some clinical settings. Ceftazidime/avibactam renal dose adjustment has recently been identified as an independent risk factor for mortality.

Objectives

To investigate the effect of ceftazidime/avibactam renal dose adjustment on mortality.

Methods

Patients with KPC-Kp BSI treated with a ceftazidime/avibactam-based regimen were retrospectively collected and analysed. The primary outcome was mortality at 7, 14 and 30 days after the start of definitive ceftazidime/avibactam antibiotic therapy. Renal function was estimated using the CKD-EPI

SUBMITTER: Oliva A 

PROVIDER: S-EPMC11649808 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature